MedTrace Logo

Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women

NCT00828542 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women.

Conditions

  • Breastfeeding
  • Contraception

Interventions

DRUG

etonogestrel implant

Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)

DRUG

depot medroxyprogesterone acetate

150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Carolina S Vieira, MD, PhD · University of Sao Paulo

  • Milena B Brito, MD · University of Sao Paulo

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00828542 on ClinicalTrials.gov